JAK1 and primary cutaneous T-cell non-Hodgkin lymphoma: The JAK/STAT signaling pathway, central to the pathophysiology of CTCL, is frequently dysregulated through JAK1, JAK3, STAT3, and STAT5B point mutations and copy number gains in JAK2, STAT3, and STAT5B [14,15,16,17].